Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 69712. Отображено 100.
05-01-2012 дата публикации

Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Номер: US20120003318A1
Автор: Carlos A. Schuler, Rangachari Narasimhan
Принадлежит: Incarda Therapeutics Inc

Methods of treating atrial arrhythmia include administering an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof, such that the at least one antiarrhythmic pharmaceutical agent first enters the heart through the pulmonary vein to the left atrium. Other methods of treating atrial arrhythmia include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. An amount of the at least one antiarrhythmic pharmaceutical agent may peak in the coronary sinus of the heart at a time ranging from 10 seconds to 30 minutes from initiation of the administering. Unit doses, aerosols, and kits are also contemplated.

Подробнее
Номер записи: 1
05-01-2012 дата публикации

Method of reducing multi-drug resistance using inositol tripyrophosphate

Номер: US20120003327A1
Автор: Claudine Kieda, Jean-Marie Lehn, Yves Claude Nicolau
Принадлежит: Individual

Inositol trisphosphate (ITPP) causes normalization of tumor vasculature and is a particularly effective cancer therapy when a second chemotherapeutic agent is administered following partial vascularization. ITPP also treats, alone or in combination, multi-drug resistant cancers. ITPP can also be used to reduce the amount of a second chemotherapeutic drug required for anticancer activity. In addition, ITPP enhances immune response and treats hyperproliferative disorders.

Подробнее
Номер записи: 2
05-01-2012 дата публикации

Chroman derivatives, medicaments and use in therapy

Номер: US20120004296A1
Автор: Alan Husband, Andrew Heaton
Принадлежит: Marshall Edwards Inc

Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.

Подробнее
Номер записи: 3
12-01-2012 дата публикации

Prebiotic Formulations for use with Probiotics to Increase Probiotic Growth Rate and Activity

Номер: US20120009239A1
Автор: Randolph S. Porubcan, Sonja Lea Yonak
Принадлежит: MASTER SUPPLEMENTS Inc

Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or where they are to be combined with probiotics in a carrier, or they can be treated to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.

Подробнее
Номер записи: 4
12-01-2012 дата публикации

Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids

Номер: US20120010280A1
Автор: Danilo Aleo, Maria Grazia Antonietta Saita, Maurizio Rolando, Sergio Mangiafico, Stefano Barabino
Принадлежит: TRB CHEMEDICA INTERNATIONAL SA

The invention concerns topical compositions for the prevention and treatment of ocular pathologies, in particular inflammatory keratites and conjunctivites and dry eye syndrome, containing as active ingredients polyunsaturated fatty acids of the types omega-3 and omega-6, and specifically EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid) and GLA (γ-linolenic acid), mixed with vitamin E acetate and formulated in a stable composition in hydrogel, i.e. in dispersed form in an aqueous vehicle containing one or more gelling polymers. The proposed compositions are particularly indicated for use as artificial tears.

Подробнее
Номер записи: 5
19-01-2012 дата публикации

Enhanced Natural Colors

Номер: US20120014934A1
Автор: Jeffrey M. Wuagneux, Paul Altaffer, Pi-Yu Hsu
Принадлежит: RFI LLC

A natural color is concentrated to intensify color range and to provide useful amounts of one or more of anti-oxidant, nutritional, and anti-inflammatory compounds derived from one or more pigment sources. In a preferred embodiment, the pigment source is a fruit, a vegetable, a legume, a spice, algae, or a combination thereof.

Подробнее
Номер записи: 6
19-01-2012 дата публикации

Modified release formulations containing drug-ion exchange resin complexes

Номер: US20120015030A1
Автор: Ketan Mehta, Yu-Hsing Tu
Принадлежит: Tris Pharma Inc

A solid dose composition containing a mixture of a cured, modified release-barrier coated methylphenidate-ion exchange resin complex-matrix and an uncoated methylphenidate-ion exchange resin complex is described. The barrier coated methylphenidate-ion exchange resin complex-matrix comprises methylphenidate complexed with a pharmaceutically acceptable ion-exchange resin to form the complex which is admixed with a polymer to form a methylphenidate-ion exchange resin complex-matrix, which is subsequently coated with a modified release coating. The modified coating contains polyvinyl acetate polymer and a plasticizer and is cured.

Подробнее
Номер записи: 7
26-01-2012 дата публикации

Methods for accelerating wound healing by administration of adipokines

Номер: US20120020917A1
Автор: Inessa Solomonik, Liora Braiman-Wiksman
Принадлежит: Individual

Methods for inducing or accelerating a healing process of a damaged skill or skin wounds are described. The methods include administering to the skin cells colonizing the damaged skin or skin wound a therapeutically effective amount of an adipokine, an adipocyte or preadipocyte modulator, adipocytes, preadipocytes, or stem cells, or transforming the skin cells colonizing the damaged skin or skin wound such as to express and secrete an adipokine, thereby inducing or accelerating the healing process of the damaged skin or skin wound.

Подробнее
Номер записи: 8
26-01-2012 дата публикации

Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle

Номер: US20120022001A1
Автор: David F. Driscoll
Принадлежит: STABLE SOLUTIONS LLC

A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.

Подробнее
Номер записи: 9
26-01-2012 дата публикации

Use of aminaphtone for the preparation of a medicament for treating arteriopathies

Номер: US20120022155A1
Автор: Raffaella Scorza
Принадлежит: Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

The subject of the present invention is the use of aminaphtone for the preparation of a medicament for treating arteriophaties, in particular arteriophaties of a degenerative inflammatory type. Preferably, said medicament is formulated for oral administration

Подробнее
Номер записи: 10
26-01-2012 дата публикации

Delayed release, oral dosage compositions that contain amorphous cddo-me

Номер: US20120022156A1
Автор: Colin J. Meyer, Jiang Zhang
Принадлежит: Reata Pharmaceuticals Inc

Pharmaceutical formulations exhibit a desirably low Cmax, among other properties, that contain particles of amorphous bardoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based on the crystalline form of bardoxolone methyl.

Подробнее
Номер записи: 11
26-01-2012 дата публикации

Dosing and monitoring patients on nitrogen-scavenging drugs

Номер: US20120022157A1
Автор: Bruce Scharschmidt
Принадлежит: Ucyclyd Pharma Inc

The invention provides a method for determining a dose and dosing schedule, and making dose adjustments of patients taking PBA prodrugs as nitrogen scavengers to treat nitrogen retention states, including ammonia accumulation disorders as well as chronic renal failure, by measuring urinary excretion of phenylacetylglutamine and/or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered waste nitrogen scavenging drug, and to monitoring patients receiving such drugs.

Подробнее
Номер записи: 12
02-02-2012 дата публикации

Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids

Номер: US20120029079A1
Автор: Charles R. Wolf, Clifford R. Elcombe
Принадлежит: CXR Biosciences Ltd

The molecules of formula (I) are useful in treating diabetes, obesity, hypercholesterolaemia, hyperlipidaemia, cancer, inflammation or other conditions in which modulation of lipis of eicosanoid status or functions may be desirable. Formula (I): Z 1 —Z 1 —Z 2 wherein a) Z 1 represents CO 2 H or a derivative thereof; b) Z 2 represents F, H, —CO 2 H or a derivative thereof; and c) X represents fluorinated alkylene; or a solvate thereof, for example a perfluorinated fatty acid or derivative thereof.

Подробнее
Номер записи: 13
09-02-2012 дата публикации

Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging

Номер: US20120035250A1
Автор: Dayan Goodenowe, M. Amin Khan, Paul L. Wood, Pearson Ahiahonu, Rishikesh Mankidy
Принадлежит: Phenomenome Discoveries Inc

Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).

Подробнее
Номер записи: 14
23-02-2012 дата публикации

Anti-oxidant lozenges for the prevention and treatment of radiation induced mucositis, precancerous lesions, oral cancer and other oral cavity mucosal disorders

Номер: US20120046354A1
Автор: Eli D. Ehrenpreis
Принадлежит: Individual

A method for treating or preventing oral cavity mucosal disorders, comprising a step of providing a lozenge containing an antioxidant selected from the group of Vitamin A, Vitamin C, Vitamin E; and other ingredients and a step of placing the lozenge within the oral cavity for a period of time required for dissolution of the lozenge.

Подробнее
Номер записи: 15
01-03-2012 дата публикации

Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis

Номер: US20120053141A1
Автор: Jianhua Xu, Lurong Zhang, Shanmin Yang, Weijian Zhang
Принадлежит: Individual

The present invention pertains to novel uses of glycyrrhetinic acid (GA), glycyrrhizic acid (GLA) and related compounds for prevention and/or treatment of pulmonary fibrosis, in particular, irradiation-induced pulmonary fibrosis. Also embodied are therapeutic uses of prodrugs, metabolites, derivatives (e.g., acids, esters and ethers), and salts of glycyrrhetinic acid (GA) and glycyrrhizic acid (GLA). The present invention also provides for therapeutic or pharmaceutical compositions comprising a compound of the invention in a form that can be combined with a pharmaceutically acceptable carrier.

Подробнее
Номер записи: 16
01-03-2012 дата публикации

(R)-(-)-1,2-propanediol compositions and methods

Номер: US20120053152A1
Автор: Edward T. Wei
Принадлежит: Individual

Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor. In one embodiment of this invention, (R)-1,2-propanediol is used as an alcoholic solvent for the topical delivery of cooling agents to biological surfaces. This propanediol enantiomer has a minimum inhibitory effect on cooling with respect to standard 2- to 3-carbon alcoholic solvents, and functions to substantially protect the agent's cooling activity from inhibition when in the presence of a short-chain alcohol.

Подробнее
Номер записи: 17
01-03-2012 дата публикации

Pharmaceutical composition for diabetic nephropathy and its preparation and application

Номер: US20120053236A1
Автор: Bao He, Dan Tang, Fei GU, Huiquan Cheng, Quan Zhu, Rushang Wang, Tingting Duan, Xiaoling Huang, Xinghua Shi, Yanxia Huang, Zhaoguang Zheng
Принадлежит: GUANGZHOU CONSUN MEDICINE R AND D CO Ltd

The invention relates to application of 4,4′-diphenylmethane-bis(methyl) carbamates (DPMC) extracted and isolated from Cortex Mori and preparation of medicine for diabetic nephropathy. The pharmaceutical composition is made up of DPMC as active ingredient and the normal drug carriers, and the weight percentage of active ingredient is 0.1-99.5%. For the remarkable effect of prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients.

Подробнее
Номер записи: 18
08-03-2012 дата публикации

Pharmaceutical compositions and methods for treating tuberculosis

Номер: US20120058977A1
Автор: Lubbert Dijkhuizen, Martin Ostendorf, Peter Van Der Meijden, Robert Van Der Geize
Принадлежит: Rijksuniversiteit Groningen

A pharmaceutical composition for the treatment of a disease caused by a bacterium that belongs to the group of nocardioform actinomycetes, said composition comprising an effective amount of a compound selected from compound I, (+)-compound II, (−)-compound II, compound III, or mixtures thereof.

Подробнее
Номер записи: 19
08-03-2012 дата публикации

Compositions and methods for treating cancer and methods for predicting a response to such treatments

Номер: US20120059021A1
Автор: Andy J. Chien, Rachel TORONI, Randall T. Moon, Rima KULIKAUSKAS, Travis L. Biechele
Принадлежит: UNIVERSITY OF WASHINGTON

The present disclosure relates to the regulation and function of the Wnt/β-catenin signaling pathway and the ERK signaling pathway. The disclosure provides methods of treatment for melanoma by administering both an inhibitor of ERK signaling and an activator of Wnt/β-catenin signaling. These methods may be used alone or in combination with other strategies targeting melanoma cell survival. The disclosure also provides diagnostic methods for predicting a patient's clinical response to inhibitors of ERK signaling.

Подробнее
Номер записи: 20
08-03-2012 дата публикации

Combinations comprising antimuscarinic agents and pde4 inhibitors

Номер: US20120059031A1
Автор: Hamish Ryder, Jesus Llenas Calvo, Jordi Gras Escardo, Pio Orviz Diaz
Принадлежит: Individual

A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.

Подробнее
Номер записи: 21
08-03-2012 дата публикации

Antiviral treatments

Номер: US20120059057A1
Автор: John Michael Kilpatrick, Pooran Chand, Shane Arnold, Shanta Bantia, Yarlagadda Sudhakara Babu
Принадлежит: BioCryst Pharmaceuticals Inc

The invention provides unit dosage forms, kits, and methods useful for treating viral infections.

Подробнее
Номер записи: 22
08-03-2012 дата публикации

Dispersions of rasagiline citrate

Номер: US20120059058A1
Автор: David Engers, Keith Lorimer
Принадлежит: Teva Pharmaceutical Industries LTD

The subject invention provides a solid dispersion of rasagiline citrate, a composition and a process for the manufacture thereof.

Подробнее
Номер записи: 23
22-03-2012 дата публикации

Metallo-beta-lactamase inhibitors

Номер: US20120071457A1
Автор: Akihiro Morinaka, Ken Chikauchi, Mizuyo Ida, Takao Abe, Toshiaki Kudo, Yukiko Hiraiwa
Принадлежит: Individual

A new metallo-β-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of β-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-β-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of β-lactam antibiotics against metallo-β-lactamase producing bacteria by combining the compound of the general formula (I) with β-lactam antibiotics.

Подробнее
Номер записи: 24
29-03-2012 дата публикации

Pharmaceutical product

Номер: US20120077856A1
Автор: Masayuki Ii, Tomohiro Kawamoto, Yuji Iizawa
Принадлежит: Takeda Pharmaceutical Co Ltd

An agent for suppressing the production of various cytokines (IL-8 and the like) and inflammatory mediators, an agent for suppressing the expression of COX-II and the like, or an inhibitor of various phosphorylation enzymes (ATF2 and the like), which contains a TLR signaling inhibitory substance, preferably a compound represented by the formula (I) or the formula (II) wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

Подробнее
Номер записи: 25
12-04-2012 дата публикации

Therapeutics for age-related macular degeneration

Номер: US20120087928A1
Автор: Kameran Lashkari
Принадлежит: Individual

The invention provides compositions and methods of predicting a subject's risk of developing age-related macular degeneration (AMD) and methods of treating, delaying, or preventing the development and progression of AMD.

Подробнее
Номер записи: 26
12-04-2012 дата публикации

Satiety-inducing composition

Номер: US20120088830A1
Автор: Annika Viberg, Anthonius Cornelis Van Den Burg, Arjen Sein, Damiet Josephina Petronella Cunera Koenders, Gerardus Johannes Franciscus Smolders
Принадлежит: DSM IP ASSETS BV

The present invention relates to the field of weight management. The invention particularly relates to a method for inducing satiety. In one of its embodiments, the present invention provides a method for inducing satiety in a human or an animal comprising administering to said human or animal an effective amount of a composition comprising a lipid of which at least part is in a crystal form in the small intestine.

Подробнее
Номер записи: 27
19-04-2012 дата публикации

Compositions comprising a radiosensitizer and an anti-cancer agent and methods of uses thereof

Номер: US20120093918A1
Автор: Gabriel Charest, Leon Sanche
Принадлежит: SOCPRA Sciences Sante et Humaines sec

A combination of an anti-cancer agent and a metal radiosensitizer potentiates the radiotherapy of cancer. Said anti-cancer agent is preferably cisplatin while the metal radiosensitizer is preferably gold nanoparticles. Both the anti-cancer agent and the metal radiosensitizer bind to DNA and potentiate the radiotherapy of cancer by synergistically increases the amount of double strand breaks induced by the radiation. The anti-cancer agent and the metal radiosensitizer may be encapsulated in liposomes.

Подробнее
Номер записи: 28
19-04-2012 дата публикации

Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses, Or Conditions

Номер: US20120093923A1
Автор: Frederick H. Miller, Gary D.E. Pierce, James H. Ruble
Принадлежит: INNERCAP Technologies Inc

A method and apparatus for delivering a plurality of medicaments in a single delivery vehicle for the management of co-morbid diseases, illnesses and conditions. The present invention provides a novel delivery process for many medicaments. Medicaments may be encapsulated and stored separately within a larger capsule until the time of ingestion, consumption, or the like. Benefits of the present invention include maintaining separation of distinct ingredients within a single capsule and the capability to control the time release of multiple ingredients within the capsule.

Подробнее
Номер записи: 29
19-04-2012 дата публикации

Methods of treating hypertriglyceridemia

Номер: US20120093924A1
Автор: Ian OSTERLOH, Mehar Manku, Paresh Soni, Pierre Wicker, Rene Braeckman
Принадлежит: Amarin Pharma Inc

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Подробнее
Номер записи: 30
19-04-2012 дата публикации

Bioavailability Enhancement Delivery System

Номер: US20120095098A1
Автор: Bhiku Patel
Принадлежит: PruGen IP Holdings Inc

A composition for increasing the bioavailability of drugs in humans and animals comprising a microemulsion further comprising a first emulsifier, a second emulsifier, and an oil wherein the emulsifiers have individual HLB values of between about 10 and about 30, are in a ratio ranging from about 1:1 to about 4:1; and, the first and second emulsifier combination and oil are in a ratio of about 99:1 to about 9:1. A method for increasing the bioavailability of such a composition is also provided.

Подробнее
Номер записи: 31
26-04-2012 дата публикации

Stable pharmaceutical composition and methods of using same

Номер: US20120100208A1
Автор: Mehar Manku
Принадлежит: Amarin Pharma Inc

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.

Подробнее
Номер записи: 32
03-05-2012 дата публикации

Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same

Номер: US20120107383A1
Автор: William F. Mckay
Принадлежит: WARSAW ORTHOPEDIC INC

Osteoconductive matrices and methods are provided that have one or more statins disposed in calcium phosphate particles. The matrices may be injected into a fracture site. The osteoconductive matrices provided allow for sustained release of the statin and facilitate bone formation and repair of the fracture site.

Подробнее
Номер записи: 33
03-05-2012 дата публикации

Pharmaceutical formulations and methods for treating respiratory tract infections

Номер: US20120107414A1
Автор: David L. Hava, John Hanrahan, Michael M. Lipp, Richard Batycky, Robert W. Clarke
Принадлежит: Pulmatrix Inc

The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca +2 to Na + is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.

Подробнее
Номер записи: 34
10-05-2012 дата публикации

Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof

Номер: US20120114742A1
Автор: Alexa L. Martinez, L. David Williams, Mark G.P. Saifer, Merry R. Sherman
Принадлежит: Mountain View Pharmaceuticals Inc

Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.

Подробнее
Номер записи: 35
17-05-2012 дата публикации

Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas

Номер: US20120122940A1
Автор: Anne Kristin Holmeide, Morten Braendvang, Ragnar Hovland, Tore Skjæret
Принадлежит: Individual

The present disclosure relates to lipid compounds of the general formula (I): R1-O—C(R2)(R3)-X  (I) wherein R 1 is a C 10 -C 22 alkyl group, a C 10 -C 22 alkenyl group having 1-6 double bonds, or a C 10 -C 22 alkynyl group having 1-6 triple bonds; R 2 and R 3 are the same or different and may be chosen from different substituents; and X is a carboxylic acid or a derivative thereof, such as a carboxylic ester, a carboxylic anhydride, a phospholipid, triglyceride, or a carboxamide; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic, and inflammatory disease area.

Подробнее
Номер записи: 36
17-05-2012 дата публикации

Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment

Номер: US20120122978A1
Автор: Samuel T. Henderson
Принадлежит: Accera Inc

This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal.

Подробнее
Номер записи: 37
17-05-2012 дата публикации

Methods of Treating Fragile X Syndrome

Номер: US20120122986A1
Автор: Kathryn Roberts, Mark F. Bear, Randall L. Carpenter
Принадлежит: Seaside Therapeutics Inc

Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen.

Подробнее
Номер записи: 38
24-05-2012 дата публикации

Topical Pharmaceutical Foam Composition

Номер: US20120128598A1
Автор: Jane C. Hirsh, Mark W. Trumbore, Ronald M. Gurge
Принадлежит: Precision Dermatology Inc

A stable topical alcohol-free aerosol foam containing one or more keratolytic agents is provided. The foam-forming formulation is an oil-in-water emulsion which contains one or more hydrofluoroalkane (HFA) propellants and one or more keratolytic agents. The keratolytic agent may be present in either phase of the emulsion or dispersed in the emulsion. The oil phase may consist at least in part of the HFA propellant. The foam is stable on the skin for at least 5 minutes at body temperature and disappears into the skin upon rubbing or after prolonged standing. The formulations may not contain additional co-solvents or non-HFA co-propellants. The formulations demonstrate reduced intensity of the odor and/or color associated with the keratolytic agent(s) as compared to conventional formulations containing keratolytic agents.

Подробнее
Номер записи: 39
24-05-2012 дата публикации

Alkyl Sulfosuccinate Mixtures, And Use Thereof

Номер: US20120128601A1
Автор: Almud Folge, Ansgar Behler, Catherine Weichold, Helga Gondek, Rainer Eskuchen
Принадлежит: Cognis IP Management GmbH

The invention relates to mixtures of alkyl sulfosuccinate monoesters of general formulas (I) and/or (II), in which R represents a linear or branched, saturated or unsaturated alkyl group having 6 to 22 C atoms, and X and Y independently represent a hydrogen atom or a cation that can form a water-soluble salt and is selected from among the group composed of alkali metal, alkaline earth metal, ammonia, and organic ammonia. The invention is characterized in that the mixture contains 30 to 70 percent by weight of C16 alkyl sulfosuccinate monoester and 30 to 70 percent by weight of C18 alkyl sulfosuccinate monoester, the percentages by weight being in relation to the total amount of alkyl sulfosuccinate monoesters of formulas (I) and (II). The invention also relates to the use of said mixtures in cosmetic and/or pharmaceutical preparations.

Подробнее
Номер записи: 40
24-05-2012 дата публикации

Pentamidine combinations for treating cancer

Номер: US20120128667A1
Автор: Chiaoli Yeh, David Griller, Terry Chow
Принадлежит: Oncozyme Pharma Inc

The present invention relates to the treatment of cancer, e.g., ovarian cancer, breast cancer, pancreatic cancer or colon cancer, with pentamidine and (a) oxaliplatin, (b) gemcitabine, (c) taxol, (d) 5-fluorouracil or (e) CPT 11.

Подробнее
Номер записи: 41
24-05-2012 дата публикации

Treatment of eye discomfort by topical administration of a cooling agent to the external surface of the eyelid

Номер: US20120128754A1
Автор: Edward Tak Wei
Принадлежит: Individual

The present invention pertains generally to the field of ocular treatment, and more specifically to the use of a liquid cooling agent composition comprising a cooling agent for the treatment of (e.g., the alleviation of symptoms of; the amelioration of) eye discomfort. The preferred cooling agent is (1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarboxylic acid 2,3-dihydroxy-propyl ester (referred to herein as CPS-030). The liquid cooling agent composition is topically administered to at least a portion of the external surface of the eyelid (preferably the closed eyelid) of the eye to be treated. Preferably, the liquid cooling agent composition is carried on or in a wipe, pad, or towelette, for example, an eye wipe.

Подробнее
Номер записи: 42
31-05-2012 дата публикации

Fatty acids as anti-inflammatory agents

Номер: US20120136034A1
Автор: Bruce A. Freeman, Francisco J. Schopfer
Принадлежит: University of Pittsburgh

Compounds of formula I and their metabolites are potent mediators of an inflammatory response: (I) where a, b, c, d, e, f, V, W, X, Y, R a , R a′ , R b , R b′ , R c , and R c′ are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.

Подробнее
Номер записи: 43
31-05-2012 дата публикации

Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis

Номер: US20120136057A1
Автор: Dayan Goodenowe, M. Amin Khan, Pearson W.K. Ahiahonu, Shawn Ritchie
Принадлежит: Phenomenome Discoveries Inc

A compound of formula (I): wherein R represents a hydroxy substituted C 24 -C 40 straight chain aliphatic group containing at least one double bond in the carbon chain; and at least one carbon in the chain is substituted with a hydroxy group. Such compounds are useful for detecting inflammation, inflammatory disorders and cancer in a subject, and can also be used in therapeutic applications including treatment and/or prevention of these conditions. Pharmaceutical compositions, combinations and supplements, as well as methods of treatment using the described compounds are therefore also described.

Подробнее
Номер записи: 44
07-06-2012 дата публикации

Nutritional supplement

Номер: US20120141447A1
Автор: Ford D. Albritton, Iv
Принадлежит: Individual

A nutritional supplement for inhibiting sensorineural hearing loss includes from about 0.25 to about 6.0 wt. % thiamin, from about 0.1 to about 10 wt. % pyridoxiyl-5-phosphate, from about 0.01 to about 10 wt. % folic acid, from about 0.025 to about 4.0 wt. % hydroxycobalamin, from about 1 to about 7 wt. % magnesium, from about 0.25 to about 6.0 wt. % zinc, from about 0.001 to about 0.02 wt. % selenium, from about 0.1 to about 10 wt. % manganese, from about 5 to about 50 wt. % ginger root P.E. 4:1., from about 5 to about 40 wt. % citrus bioflavonoids, from about 2.5 to about 40 wt. % 1-cystine, from about 5 to about 40 wt. % n-acetlyl-1-carnitine, from about 1 to about 40 wt. % alpha lipoic acid, from about 1 to about 40 wt. % coenzyme Q10, from about 1 to about 40 wt. % green tea extract, and from about 1 to about 60 wt. % resveratrol.

Подробнее
Номер записи: 45
07-06-2012 дата публикации

Pharmaceutical composition including a dha ester to be administered parenterally

Номер: US20120141563A1
Автор: Elie Leverd, Elsa Kung, Mathew Leigh, Peter Van Hoogevest
Принадлежит: Pierre Fabre Medicament SA

The present invention relates to a pharmaceutical composition to be parenterally administered, including submicronic ester particles of docosahexaenoic acid, dispersed in an aqueous phase using a mixture of at least two surfactants selected from among a) at least one polyoxyethylene fatty acid ester and b) at least one phospholipid derivative. The present invention also relates to the method for preparing said pharmaceutical composition.

Подробнее
Номер записи: 46
07-06-2012 дата публикации

Compositions and methods relating to proliferative diseases

Номер: US20120141578A1
Автор: Chandagalu D. Raghavendragowda, Gajanan S. INAMDAR, Gavin P. Robertson, Omer F. Kuzu, Subbarao V. Madhunapantula
Принадлежит: PENN STATE RESEARCH FOUNDATION

Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described herein.

Подробнее
Номер записи: 47
14-06-2012 дата публикации

Use of jasmonate to treat bladder dysfunction

Номер: US20120149655A1
Автор: Brunde Broady
Принадлежит: Broady Health Sciences LLC

A formulation or composition contractility comprising jasmonate for modulating bladder and/or treating bladder dysfunction, particularly an overactive bladder in a mammal, particularly a human and use of jasmonate for treating bladder dysfunction is provided.

Подробнее
Номер записи: 48
14-06-2012 дата публикации

process for preparing trichloroammineplatinate salt and the products obtained therein

Номер: US20120149907A1
Автор: Jan Mengler, Karel Havlovic, Libor Cerveny, Lucie Potucka, Petr Kacer, Vladimir Kysilka
Принадлежит: VUB Pharma AS

The present invention relates to a process for preparing a trichloroammineplatinate salt by reacting a tetrachloroplatinate salt in aqueous solution in the presence of ammonium chloride and an alkali chloride with one or more carbonate salts selected from the group consisting of potassium, sodium and ammonium carbonate while keeping the pH value below 7 during the reaction; the product obtained therein and a use thereof.

Подробнее
Номер записи: 49
14-06-2012 дата публикации

Antimicrobial material and method for making the same

Номер: US20120150095A1
Автор: Michael Szycher
Принадлежит: Individual

This invention provides a modified catheter/indwelling device biomaterial that provides both immediate, and long-term microbiocidal effects on otherwise antibiotic-resistant strains of microorganisms. The material, which exhibits good mechanical performance characteristics for medical devices, is composed of a hydrophobic polyurethane (PU), a hydrophilic polyethylene vinyl acetate (PEVA) as an option, a soluble silver salt and a sparsely-soluble silver salt. The hydrophobic polyurethane provides the good physical properties, the PEVA the hydrophilicity necessary to allow some water ingress into the catheter, the soluble silver salt for an immediate burst effect, and the sparsely-soluble silver salt for sustained-release over many months postimplantation. Alternatively, the sparsely soluble silver salt can be silver iodate and is combined with silver sulfadiazine. Chlorhexidine can also be included in the material.

Подробнее
Номер записи: 50
21-06-2012 дата публикации

Combination therapy for cancer comprising a platinum-based antineoplastic agent and a biocompatible electron donor

Номер: US20120156311A1
Автор: Qing-bin LU
Принадлежит: Individual

The combination of a biocompatible electron donor and a platinum-based antineoplastic agent exhibits improved efficacy in treating cancer This improved activity appears to be the result of electron transfer from the aforementioned donor compound to the platinum-based antineoplastic agent As the electron donor alone has no chemotherapeutic utility in treating cancer, the resulting combinations appear to be synergistic in nature In select preferred embodiments, the biocompatible electron donor is an amine (such as N,N,N′,N′-tetramethyl-p-phenylene diamine or indocyanine green), a phenolic compound (such as a flavanol or catechin), or a quinone (such as an aromatic quinone), while the antineoplastic is cisplatin.

Подробнее
Номер записи: 51
21-06-2012 дата публикации

Methods of treating hypertriglyceridemia

Номер: US20120157530A1
Автор: Ian OSTERLOH, Mehar Manku, Paresh Soni, Pierre Wicker, Rene Braeckman
Принадлежит: Amarin Pharma Inc

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Подробнее
Номер записи: 52
05-07-2012 дата публикации

Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof

Номер: US20120172327A1
Автор: Geralyn O. Duska-Mcewen, Joseph P. Schaller, Rachael Buck
Принадлежит: ABBOTT LABORATORIES

Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.

Подробнее
Номер записи: 53
05-07-2012 дата публикации

Chroman derivatives, medicaments and use in therapy

Номер: US20120172424A1
Автор: Alan Husband, Andrew Heaton
Принадлежит: Marshall Edwards Inc

Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.

Подробнее
Номер записи: 54
05-07-2012 дата публикации

Omega 3 fatty acid formulations

Номер: US20120172431A1
Автор: Ann Coric, Louis C. Sanfilippo, Seth D. Feuerstein
Принадлежит: CENESTRA LLC

The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof.

Подробнее
Номер записи: 55
05-07-2012 дата публикации

Liver Regeneration Accelerator Comprising Betaine

Номер: US20120172436A1
Автор: Young Chul Kim
Принадлежит: SNU R&DB FOUNDATION

The present invention relates to betaine or a composition comprising the same for accelerating liver regeneration, more particularly, a therapeutic pharmaceutical composition comprising betaine represented by formula 1 as an active ingredient for promoting the recovery of injured or resected liver to the normal liver. The most effective treatment for chronic liver disease, particularly in the terminal stage, is hepatectomy and liver transplantation. In Living Donor Liver Transplantation (LDLT) that has been increasing since 1990, rapid regeneration of liver tissues is essential for both donor and recipient to inhibit complications and thus for the success of the treatment. Betaine accelerates the recovery and growth of injured liver to the normal liver, so that it can be effectively used for the successful LDLT or therapeutic hepatectomy.

Подробнее
Номер записи: 56
19-07-2012 дата публикации

Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases

Номер: US20120183593A1
Автор: Clyde Schultz
Принадлежит: DirectContact LLC

This invention provides a polymeric drug delivery system including a hydrogel containing one or more drugs for the treatment of a posterior segment disease. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concentrations of compounds, e.g., from eye drops.

Подробнее
Номер записи: 57
19-07-2012 дата публикации

Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance

Номер: US20120184578A1
Автор: Vincent I. Teow
Принадлежит: Heptiva LLC

Compositions of hepatic therapeutic actives from one or more acridone compounds, one or more xanthone compounds, one or more thioxanthone compounds, one or more tocotrienol compounds, and one or more oleanolic triterpenoid compounds. Also, methods for treating various liver diseases or certain cancers with such hepatic therapeutic actives, as well as providing liver health maintenance.

Подробнее
Номер записи: 58
19-07-2012 дата публикации

Methods for treating inflammation

Номер: US20120184616A9
Автор: Dakai Liu, Elazar Rabbani, James J. Donegan, Richard Jin, Riddhi Bhattacharyya, Wei Cheng, Xiaofeng Li, Yazhou Zhang
Принадлежит: Individual

The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.

Подробнее
Номер записи: 59
26-07-2012 дата публикации

Method of using beta-hydroxy-beta-methylbutyrate and fatty acids for treating disease-associated wasting

Номер: US20120189717A1
Автор: Anne C. Voss, Jeffrey H. Baxter, Michael J. Tisdale, Pradip Mukerji
Принадлежит: ABBOTT LABORATORIES

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ω-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.

Подробнее
Номер записи: 60
26-07-2012 дата публикации

Androgen composition for treating an opthalmic condition

Номер: US20120190661A1
Автор: Adnan K.. Salameh, Anuradha V. Gore, Chetan P. Pujara, Jaya Giyanani, John T. Trogden
Принадлежит: Allergan Inc

The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. The disclosure further provides methods for treating an ocular condition with the disclosed compositions.

Подробнее
Номер записи: 61
02-08-2012 дата публикации

Diagnosis and treatment of the prodromal schizophrenic state

Номер: US20120195984A1
Автор: Jay L. Lombard
Принадлежит: Genomind Inc

Described herein are compounds (including medical foods, pharmaceutical compositions, methods of compounding them), methods and systems for the diagnosis and/or treatment of prodromal schizophrenia. For example, described herein are methods of treating a developmentally-based neuropsychiatric disorder (schizophrenia) that includes first determining if a subject is at risk for such a disorder by examining phenotypical, serological immune markers and genotypical biomarkers. The biomarkers may be used to tailor the dose to be delivered by the medial food or pharmaceutical composition. Also described are compounds for treating prodromal (rather than full-blown) schizophrenia.

Подробнее
Номер записи: 62
02-08-2012 дата публикации

Kits and improved compositions for treating lower urinary tract disorders

Номер: US20120196830A1
Автор: C. Lowell Parsons
Принадлежит: Individual

Superior buffered formulations and their kits for treating lower urinary tract symptoms and disorders are provided in the invention. In particular superior buffered formulations have demonstrated improvement for treating lower urinary tract symptoms of patients experiencing severe pain and/or urgency of the bladder and associated areas of the lower urinary tract.

Подробнее
Номер записи: 63
02-08-2012 дата публикации

Composition comprising a pde4 inhibitor and a pde5 inhibitor

Номер: US20120196867A1
Автор: Armin Hatzelmann, Christian Schudt, Friedrich Grimminger, Hossein Ardeschir Ghofrani, Torsten Dunkern
Принадлежит: NYCOMED GMBH

The claimed subject matter relates to pharmaceutical compositions comprising a PDE4 inhibitor and a PDE5 inhibitor and the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) is detrimental.

Подробнее
Номер записи: 64
09-08-2012 дата публикации

Pharmaceutical Compositions

Номер: US20120201888A1
Автор: Bernard Schachtel, John Ameling, Paul Bosse, Ray Takigiku
Принадлежит: Charleston Laboratories Inc

Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.

Подробнее
Номер записи: 65
16-08-2012 дата публикации

(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability

Номер: US20120208880A1
Автор: Gerrit Hauck
Принадлежит: SANOFI SA

The invention relates to solid pharmaceutical compositions comprising (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.

Подробнее
Номер записи: 66
16-08-2012 дата публикации

L-ornithine phenyl acetate and methods of making thereof

Номер: US20120208885A1
Автор: Attilia Figini, Christine Henderson Dougan, Jim Behling, Keith Anderson, Peter Manini, Stephen William Watt
Принадлежит: Ocera Therapeutics Inc

Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Подробнее
Номер записи: 67
23-08-2012 дата публикации

Methods of producing and using nutritional and pharmaceutical compositions that include one or more active substances

Номер: US20120214755A1
Автор: Erwin Denk
Принадлежит: Individual

Methods for producing a composition that includes an active agent, nutraceutical and pharmaceuticals compositions, and methods for ameliorating and/or treating a disease using the composition that includes an active substance are described herein. More particularly, methods for producing a composition that contains one or more active substances such as oleocanthal, pharmaceutical compositions that include one or more active substances such as oleocanthal, and methods of ameliorating and/or treating inflammation using compositions that contains one or more active substances such as oleocanthal are described.

Подробнее
Номер записи: 68
23-08-2012 дата публикации

Compounds for treatment of cell proliferative diseases

Номер: US20120214850A1
Автор: Alexander Levitzki, Izabela Fokt, Moshe Talpaz, Nicholas Donato, Slawomir Szymanski, Waldemar Priebe
Принадлежит: Individual

The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.

Подробнее
Номер записи: 69
23-08-2012 дата публикации

Methods for diagnosis and treatment of chronic fatigue syndrome

Номер: US20120214870A1
Автор: Allan Mark Evans, Peter Lance Wigley, Stephanie Elizabeth Reuter
Принадлежит: University of South Australia

Methods for the diagnosis and treatment of chronic fatigue syndrome (CFS) are disclosed based upon the finding that particular individual acylcarnitines are present in modified concentrations (ie decreased or increased concentrations) in CFS patients compared to healthy control subjects. In one form of the invention, a diagnostic method comprises determining a concentration of at least one individual acylcarnitine compound (eg oleyl-L-carnitine and linoleyl-L-carnitine) in a body sample from a test subject and comparing the concentration to a reference concentration, wherein a difference in the concentration of the at least one individual acylcarnitine from the test subject compared to the reference concentration is indicative of CFS. In another form of the invention, a method of treating CFS is provided which comprises administering an effective amount of a supplement comprising: at least one acylcarnitine compound selected from short-chain, medium-chain and long-chain acylcarnitines, L-carnitine (or an acylcarnitine that may be converted within a subject to L-carnitine) in combination with at least one fatty acid selected from short-chain, medium-chain and long-chain fatty acids, or at least one acylcarnitine in combination with at least one fatty acid selected from short-chain, medium-chain and long-chain fatty acids.

Подробнее
Номер записи: 70
30-08-2012 дата публикации

Method for Treating Sepsis or Septic Shock

Номер: US20120220658A1
Автор: Ana Rodriguez, Bernd W. Spur, Jean Walker, Kingsley Yin
Принадлежит: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

The present invention is a method for treating sepsis or septic shock using Lipoxin A4.

Подробнее
Номер записи: 71
30-08-2012 дата публикации

Composition With Preventive or Improvement Effect on Symptoms or Diseases Associated with Stress-Induced Behavior Disorders

Номер: US20120220660A1
Автор: Manabu Sakakibara, Yoshiyuki Ishikura
Принадлежит: Suntory Holdings Ltd

A composition with a preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders, comprising arachidonic acid and/or a compound comprising arachidonic acid as a constituent fatty acid.

Подробнее
Номер записи: 72
13-09-2012 дата публикации

Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders

Номер: US20120231062A1
Автор: Janusz Czernielewski, Michael Graeber
Принадлежит: Galderma Research and Development SNC

Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.

Подробнее
Номер записи: 73
13-09-2012 дата публикации

Coated Tablets, Their Method of Preparation, and Related Uses

Номер: US20120231077A1
Автор: Kern Lystrup, Leif Knudsen, Peter B. Samuelsen
Принадлежит: SPORTSCOM DANMARK APS

A tablet comprising a tabletted core comprising a triglyceride granulate, and an enteric coating surrounding said tabletted core. In particular, a tablet wherein the tabletted core contains esterified omega-3 fatty acids such as eicosapentaenoic acid and/or docosahexaenoic acid.

Подробнее
Номер записи: 74
13-09-2012 дата публикации

Marker associated with non-alcoholic steatohepatitis

Номер: US20120231471A1
Автор: Ayumi Sato, Takashi Yano, Tsuyoshi Harada, Yoko Wakabayashi
Принадлежит: Mochida Pharmaceutical Co Ltd

Disclosed is a novel NASH marker for use in a method for detecting NASH or evaluating the severity of NASH, which utilizes at least one factor selected from the group consisting of an IL-1 receptor antagonist, sCD40, HMGB1, sPLA2 group IIA and an sPLA2 activity as the marker. Also disclosed is a method for detecting NASH or evaluating the severity of NASH in a subject, which utilizes the marker.

Подробнее
Номер записи: 75
13-09-2012 дата публикации

Compositions and Methods for Treatment of Eye Disorders

Номер: US20120232019A1
Автор: Johan Oslob, John Burnier, Kenneth Barr, Min Zhong, Thomas Gadek, Wang Shen
Принадлежит: Sarcode Bioscience Inc

The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

Подробнее
Номер записи: 76
13-09-2012 дата публикации

Composition for ocular topical administration treatment ocular hypertension and glaucoma

Номер: US20120232139A1
Автор: Junichi Kawasaki, Ryuji Ueno, Tadashi Hayashi
Принадлежит: SUCAMPO AG

The present invention provides a composition for ocular topical administration for treating ocular hypertension and glaucoma, comprising latanoprost as an active ingredient, and (a) a polyol and/or sugar alcohol, (b) a nonionic surface active agent, and (c) an edetic acid compound. The composition of the present invention comprises lower amount of preservatives such as benzalkonium chloride comparative to the conventional product and therefore, can reduce incidence of the adverse side effects caused by the preservatives. In addition, the composition of the present invention can be stored stably at room temperatures for a long term.

Подробнее
Номер записи: 77
20-09-2012 дата публикации

Combretum laurifolium mart. extract and methods of extracting and using such extract

Номер: US20120237619A1
Автор: Matthew E. Burow, Peter Koepke, Ven Subbiah
Принадлежит: SelvaMedica LLC

A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Combretum laurifolium Mart. to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Combretum laurifolium Mart. suspended in the vehicle. A method of making an extract of Combretum laurifolium Mart. may comprise creating a component solution by treating Combretum laurifolium Mart. material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract of Combretum laurifolium Mart. may comprise components extracted using various solvents.

Подробнее
Номер записи: 78
20-09-2012 дата публикации

Methods and compositions for promoting the respiratory development of an infant

Номер: US20120238626A1
Автор: Maria MAKRIDES, Robert Gibson
Принадлежит: Womens and Childrens Health Research Institute

The present invention relates to methods for promoting respiratory development, reducing the incidence of respiratory distress, bronchopulmonary dysplasia and/or hayfever in an infant by administration of fatty acids and compositions comprising same, wherein the fatty acids are enriched with respect to docosahexaenoic acid (DHA) content.

Подробнее
Номер записи: 79
27-09-2012 дата публикации

Extended-release formulation for reducing the frequency of urination and method of use thereof

Номер: US20120244221A1
Автор: David A. Dill
Принадлежит: Wellesley Pharmaceuticals LLC

Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.

Подробнее
Номер записи: 80
27-09-2012 дата публикации

Methods for improving bone health in infants using long chain polyunsaturated fatty acids

Номер: US20120245121A1
Автор: José Maria Lopez Pedrosa, Manuel Manzano Martin, Ricardo Rueda Cabrera
Принадлежит: ABBOTT LABORATORIES

Disclosed are methods for improving bone health, strength and formation in an infant who may be susceptible to developing bone health issues from conception through adolescence. The methods include administration of a nutritional formulation including at least one LCPUFA to a woman during pregnancy and optionally during lactation and breastfeeding of an infant.

Подробнее
Номер записи: 81
04-10-2012 дата публикации

Ezatiostat for treating multiple myeloma

Номер: US20120251496A1
Автор: Michael M. Wick
Принадлежит: Telik Inc

Ezatiostat is useful for inhibiting multiple myeloma cell proliferation and treating multiple myeloma, alone or when added together with another anti-myeloma drug.

Подробнее
Номер записи: 82
04-10-2012 дата публикации

Co-Administration of An Agent Linked to an Internalization Peptide With an Anti-Inflammatory

Номер: US20120252731A1
Автор: Jonathan David Garman, Michael Tymianksi
Принадлежит: NoNO Inc

The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.

Подробнее
Номер записи: 83
04-10-2012 дата публикации

Bioavailability Enhancement Delivery Composition

Номер: US20120252906A1
Автор: Bhiku G. Patel
Принадлежит: PruGen IP Holdings Inc

A composition for increasing the bioavailability of an active pharmaceutical ingredient (“API”) in humans and animals, comprising a first water soluble surfactant having a cloud point greater than about 37° C., a second water soluble surfactant having a cloud point greater than about 37° C., wherein a mixture of the first surfactant and the second surfactant comprises a cloud point less than about 37° C.

Подробнее
Номер записи: 84
11-10-2012 дата публикации

Preventing or ameliorating agent for pigmentation

Номер: US20120258063A1
Автор: Chihiro Kondo, Takashi Yamasaki, Yuko Saitoh
Принадлежит: Pola Chemical Industries Inc

An object is to provide an external preparation for skin preferably usable to prevent or ameliorate pigmentation. The object is achieved by providing a preventing or ameliorating agent for pigmentation, consisting of a compound represented by the following general formula (1), an isomer thereof, and/or a pharmacologically acceptable salt thereof, and an external preparation for skin containing the same as a component: [wherein R 1 represents an unsubstituted aromatic group or an aromatic group having any substituent; R 2 represents a hydrogen atom, a linear chain or branched chain alkyl group having a number of carbon atom or atoms of 1 to 4, or an acyl group having a linear or branched alkyl chain having a number of carbon atom or atoms of 1 to 4; and R 3 represents a hydrogen atom or a linear chain or branched chain alkyl group having a number of carbon atom or atoms of 1 to 4.]

Подробнее
Номер записи: 85
11-10-2012 дата публикации

Composition comprising fesoterodine and fiber

Номер: US20120258171A1
Автор: Daniela Stumm, Katrin Rimkus
Принадлежит: ratiopharm GmbH

The invention relates to a pharmaceutical composition containing (a) fesoterodine and/or fesoterodine metabolites and (b) fibers, wherein the weight ratio of components (a):(b) is in the range from 1:50 to 1:2; and oral dosage forms containing the pharmaceutical composition. The invention further relates to dry methods of preparing those dosage forms.

Подробнее
Номер записи: 86
11-10-2012 дата публикации

Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents

Номер: US20120258181A1
Автор: Claudio Pisano, Loredana Vesci
Принадлежит: Sigma Tau Industrie Farmaceutiche Riunite SpA

The present invention relates to combinations between artemisinin-based potent anti-malarial agents, selected from the group consisting of ART, DHA and ARM, and a further chemotherapeutic drug selected from the group consisting of a camptothecin derivative, or a PARP-1 inhibitor, or an intercalating DNA agent, or an alkylating agent. Such combinations, showed medium to strong synergism in various models of cancer, in particular in NSCL.

Подробнее
Номер записи: 87
18-10-2012 дата публикации

Compositions for the treatment of cns-related conditions

Номер: US20120264782A1
Автор: Gregory T. Went, Laurence R. Meyerson, Timothy J. Fultz
Принадлежит: Adamas Pharmaceuticals Inc

The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.

Подробнее
Номер записи: 88
18-10-2012 дата публикации

Agent having neurotrophic factor-like activity

Номер: US20120264959A1
Автор: Munekazu Iinuma, Shoei Furukawa
Принадлежит: Nagoya Industrial Science Research Institute, Nippon Zoki Pharmaceutical Co Ltd

The present invention provides a pharmaceutical agent having high safety and a neurotrophic factor-like activity, which contains, as an active ingredient, any one compound included in fatty acids each having 8 carbon atoms (C8) or having 10 carbon atoms (C10) to 12 carbon atoms (C12) or fatty acid esters thereof, such as 3,7-dimethyloctanoic acid ethyl ester, geranic acid ethyl ester, and the like, each of which has 8 carbon atoms (C8), decanoic acid methyl ester, trans-2-decenoic acid, trans-2-decenoic acid methyl ester, trans-2-decenoic acid ethyl ester, trans-2-decenoic acid-2-decenyl ester, trans-2-decenoic acid cyclohexyl ester, trans-2-decenoic acid isopropyl ester, trans-3-decenoic acid methyl ester, trans-9-decenoic acid methyl ester, and the like, each of which has 10 carbon atoms (C10), trans-10-undecenoic acid methyl ester, trans-10-undecenoic acid ethyl ester, and the like, each of which has 11 carbon atoms (C11), and dodecanoic acid, and the like, each of which has 12 carbon atoms (C12), or salts thereof or prodrugs thereof.

Подробнее
Номер записи: 89
18-10-2012 дата публикации

Transdermal Delivery of Medicinal Cetylated Fatty Esters using Phonophoresis or Iontophoresis

Номер: US20120265119A1
Автор: Jack Bain Bookout, Raj R. Barathur
Принадлежит: Cymbiotics Inc

The use of phonophoresis or iontophoresis to enhance transdermal delivery of medicinal Cetylated fatty esters when applied in cream or gel compositions is disclosed. These compositions provide hydrophilic salt forms and penetration-enhancing vehicles that work in conjunction with phonophoresis or iontophoresis to increase the efficacy of the medicinal actives.

Подробнее
Номер записи: 90
25-10-2012 дата публикации

Compositions and improved soft tissue replacement methods

Номер: US20120269777A1
Автор: Adam L. Collette, Dennis E. Van Epps, Gregory H. Altman, Guang-Liang Jiang, Jingsong Chen, Rebecca L. Horan, Wha Bin Im
Принадлежит: Allergan Inc

The specification discloses compositions and methods for treating a soft tissue defect of an individual.

Подробнее
Номер записи: 91
25-10-2012 дата публикации

Methods and Compounds Useful to Induce Apoptosis in Cancer Cells

Номер: US20120269901A1
Автор: John C. Reed, Maurizio Pellecchia
Принадлежит: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.

Подробнее
Номер записи: 92
25-10-2012 дата публикации

Metal delivery agents and therapeutic uses of the same

Номер: US20120270850A1
Автор: Anthony Robert White, Kevin Jeffrey Barnham, Paul Stephen Donnelly
Принадлежит: University of Melbourne

The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels). Conditions in of this type include cancer and conditions characterised by or associated with oxidative damage, more specifically neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease or Huntington's disease. The invention also relates to ligands useful in the preparation of metal complexes of this type.

Подробнее
Номер записи: 93
01-11-2012 дата публикации

Sustained release latanoprost implant

Номер: US20120276186A1
Автор: Alazar N. Ghebremeskel, Lon T. Spada
Принадлежит: Allergan Inc

The present invention provides a sustained release, biodegradable intraocular latanoprost implant for reducing elevated intraocular pressure in an individual in need thereof. The implant can be configured as a film (e.g., a rolled film) or extruded filament, either of which can be inserted into the eye of the individual to provide for extended release of latanoprost for several days. Upon insertion into the eye, a rolled film may unroll to provide a film having a high surface area to volume ratio for drug diffusion.

Подробнее
Номер записи: 94
01-11-2012 дата публикации

Bone Growth Compositions and Methods

Номер: US20120276204A1
Автор: Benjamin J. REMINGTON, David J. Bearss, Kavian Shahi
Принадлежит: NeuroPro Technologies Inc

The present invention provides an improved technique for spinal fusion involving the administration of an HMG-CoA reductase inhibitor to a fusion. The HMG-CoA reductase inhibitor is preferably delivered to the site by a carrier. More preferably, the HMG-CoA reductase inhibitor is delivered to the site by a non-compressible delivery vehicle. The invention is suitable for promoting non-anatomic or heterotopic bone growth between any bony surfaces where bone growth is desired but does not naturally occur.

Подробнее
Номер записи: 95
01-11-2012 дата публикации

Lipoxin compounds and their use in treating cell proliferative disorders

Номер: US20120277311A1
Автор: Charles N. Serhan
Принадлежит: Brigham and Womens Hospital Inc

Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.

Подробнее
Номер записи: 96
01-11-2012 дата публикации

Methods and compositions for treating and preventing parenteral nutrition associated liver disease

Номер: US20120277316A1
Автор: Emma Tillman, Michael Storm, Richard A. Helms
Принадлежит: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

Methods and compositions for treating or preventing parenteral nutrition associated liver disease are provided. Methods and compositions for advancing enteral tolerance in subjects receiving enteral nutrition are provided. The methods involve the use of omega-3 fatty acid compositions. In some embodiments the omega-3 fatty acid compositions comprise docosahexanoic acid and eicosapentaenoic acid. In some embodiments the omega-3 fatty acid compositions comprise fish oil. In some embodiments the subjects to be treated are receiving parenteral nutrition. In some embodiments the subjects to be treated are infants having a low birth weight, very low birth weight, extremely low birth weight, a low gestational age, short bowel syndrome, necrotizing entercolitis, or any combination thereof.

Подробнее
Номер записи: 97
01-11-2012 дата публикации

Diacylglycerol acyltransferase genes and use thereof

Номер: US20120277451A1
Автор: Misa Ochiai
Принадлежит: Suntory Holdings Ltd

It is an object to provide a novel diacylglycerol acyltransferase. The present invention relates to a diacylglycerol acyltransferase, a polynucleotide encoding the same, and so on. The present invention provides a polynucleotide comprising the nucleotide sequence of, e.g., SEQ ID NO: 1 or 4, a polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2, an expression vector and transformant comprising the polynucleotide, a method for producing a lipid or fatty acid composition using the transformant, or a food, etc. comprising the lipid or fatty acid produced by the method.

Подробнее
Номер записи: 98
08-11-2012 дата публикации

Percutaneous absorption preparation comprising anti-dementia drug

Номер: US20120282303A1
Автор: Takeshi Ito
Принадлежит: Individual

The present invention relates to a percutaneous absorption preparation that is lower skin irritation and enables efficient transdermal administration of an anti-dementia drug. More specifically, the present invention relates to a percutaneous absorption preparation comprising an anti-dementia drug, a polymer compound having an amino group, a polyvalent carboxylate ester, a fatty acid alkyl ester, a styrenic polymer compound, and a tackifier resin.

Подробнее
Номер записи: 99
08-11-2012 дата публикации

Association between 4-benzamide and an acetylcholinesterase inhibitor, and pharmaceutical compositions containing it

Номер: US20120283244A1
Автор: Aurore Sors, Caryn Trocme-Thibierge, Florence Keime-Guibert
Принадлежит: Laboratoires Servier SAS

Association between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, and an acetylcholinesterase inhibitor. Medicinal products containing the same which are useful in the treatment of cognitive disturbances associated with cerebral ageing and with neurodegenerative diseases.

Подробнее
Номер записи: 100